For cardiologists who still verify against source guidelines
Stop second-guessing your guideline recall.
Structured, safety-validated recommendations from 8 guideline documents in under 30 seconds.
No credit card. 30 seconds to start.
Every recommendation cites the exact guideline section (e.g., ESC AF 2024, Sec 11.2) for instant verification.
Query
Evaluate Quality Before Signing Up
Including when we say "we don't know"
4
Clinical domains
AF, HF, ACS, VHD
2
Guideline bodies
ESC + ACC/AHA
<30s
Median response
Including retrieval
Anticoagulation in AF with CKD stage 4
Apixaban or edoxaban preferred over warfarin in AF with CKD 4 (CrCl 15-29). Dose reduction required.
Rivaroxaban not recommended if CrCl <30. Dabigatran contraindicated.
LVAD + new AF + heparin-induced thrombocytopenia
Guidelines do not directly address this rare intersection. Requires multidisciplinary input.
Suggested Next Steps:
- 1.Hematology consultation for HIT-safe anticoagulation
- 2.LVAD team input on anticoagulation strategy
- 3.Consider argatroban or bivalirudin bridge
Dual antiplatelet after ACS with planned CABG
Stop clopidogrel 5 days before CABG. Continue aspirin. Ticagrelor requires 3-day washout.
Ticagrelor has shorter washout (3 days) but higher bleeding risk.
Statin intensity post-MI with LDL 55
High-intensity statin remains indicated despite LDL 55. If LDL remains >55, add ezetimibe. Consider PCSK9i if >70.
Anticoagulation in AF with CKD stage 4
Apixaban or edoxaban preferred over warfarin in AF with CKD 4 (CrCl 15-29). Dose reduction required.
Rivaroxaban not recommended if CrCl <30. Dabigatran contraindicated.
LVAD + new AF + heparin-induced thrombocytopenia
Guidelines do not directly address this rare intersection. Requires multidisciplinary input.
Suggested Next Steps:
- 1.Hematology consultation for HIT-safe anticoagulation
- 2.LVAD team input on anticoagulation strategy
- 3.Consider argatroban or bivalirudin bridge
Currently in closed beta
52 cardiologists across 8 countries are stress-testing CardioHelper. In our ongoing validation program, 0% of citations have been fabricated — every source reference is traceable to actual guideline text.
Why CardioHelper?
Purpose-built for cardiology evidence lookup
Contraindication detection(Safety-critical)
Time per query
Source citations
Cross-guideline synthesis
Structured Class/LOE
Drug dosing (start → target)
Audit trail
Summary
*Includes any non-specialized AI assistant (ChatGPT, Claude, Gemini, etc.)
Dr. Zbigniew Bociąga
Interventional Cardiologist
CardioHelper started as a personal tool for cross-referencing ESC and ACC/AHA guidelines between patients. Every recommendation is curated from source guidelines. Every Class III contraindication is flagged.
Questions? contact@cardiohelper.com
Built for Clinical Rigor
Every feature designed with evidence-based medicine principles
Never Miss a Guideline Conflict
Cross-references ESC and ACC/AHA simultaneously. Surfaces evidence conflicts with resolution logic — so you see both positions, not just one.
Complete Dosing in Every Response
Every drug with INN name, starting dose → target dose. "Verify local SmPC" reminder on every response.
Contraindications Flagged Automatically
Class III (harm) prominently flagged before you read further. Automated MISMATCH detection for ungrounded recommendations.
Answers in Under 30 Seconds
Get structured recommendations while you wait. See retrieval progress live. Cancel anytime if you need to move on.
Complex Multi-Comorbidity Cases
Toggle high reasoning effort when guidelines conflict or multiple conditions overlap. Slower but more comprehensive.
Use when: Multi-comorbidity patients, conflicting guideline recommendations, drug-drug interactions
Example: Standard: 'Consider apixaban in AF with CKD' → Deep: 'Apixaban preferred per ESC AF 2024 Sec 11.2, but note interaction with amiodarone per ACC/AHA, reduce dose if CrCl <25 per SmPC, contraindicated if concurrent triple therapy'
Governance-Ready Audit Trail
Every query logged with redacted PII and validation status. Ready for your institution's clinical governance review.
Clinical Governance & Data Security
Full transparency for institutional compliance requirements.
Your patient data is scrubbed before processing. We store nothing identifiable.
Query Input
Your clinical question
PII Scrub
Names, IDs auto-removed
Guideline Retrieval
ESC + ACC/AHA matched
Synthesis
Class/LOE extraction
Validation
Safety checks applied
Query Input
Your clinical question
PII Scrub
Names, IDs auto-removed
Guideline Retrieval
ESC + ACC/AHA matched
Synthesis
Class/LOE extraction
Validation
Safety checks applied
Data Processing Agreement (DPA) available on request for institutional deployments. governance@cardiohelper.com
Simple Pricing
Free to try. Pro pays for itself in 2 queries.
Break-even: 2 queries. At €150/hr, Pro pays for itself after just 14 minutes of saved lookup time.
10 queries/month = 70 min saved = €175 of your time for €29
Free
Try it out
- 5 queries/month
- All 8 guidelines
- Standard synthesis
Pro
For daily use
Billed €276/year
- 50 queries/month
- Deep Analysis mode
- Email support
- Priority processing
Premium
Power users
Billed €756/year
- 150 queries/month
- All Pro features
- Priority support
- API accessComing Soon
API access launching Q3 2026
All plans include safety validation and audit trail. Cancel anytime.
Questions
Disclaimer: CardioHelper is informational clinical decision support. It does not diagnose, prescribe, or make treatment decisions. All decisions remain with the treating physician. Verify recommendations against local SmPC.